Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2014 Mar 3;9(3):e89511.
doi: 10.1371/journal.pone.0089511. eCollection 2014.

Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial

Sanjay Patole  1 , Anthony D Keil  2 , Annie Chang  3 , Elizabeth Nathan  4 , Dorota Doherty  5 , Karen Simmer  1 , Meera Esvaran  6 , Patricia Conway  6
Affiliations
Randomized Controlled Trial

Effect of Bifidobacterium breve M-16V supplementation on fecal bifidobacteria in preterm neonates--a randomised double blind placebo controlled trial

Sanjay Patole et al. PLoS One. .

Abstract

Background: Probiotic supplementation significantly reduces the risk of necrotising enterocolitis (NEC) and all cause mortality in preterm neonates. Independent quality assessment is important before introducing routine probiotic supplementation in this cohort.

Aim: To assess product quality, and confirm that Bifidobacterium breve (B. breve) M-16V supplementation will increase fecal B. breve counts without adverse effects.

Methods and participants: Strain identity (16S rRNA gene sequencing), viability over 2 year shelf-life were confirmed, and microbial contamination of the product was ruled out. In a controlled trial preterm neonates (Gestation <33 weeks) ready to commence or on feeds for <12 hours were randomly allocated to either B. breve M-16V (3×109 cfu/day) or placebo (dextrin) supplementation until the corrected age 37 weeks. Stool samples were collected before (S1) and after 3 weeks of supplementation (S2) for studying fecal B. breve levels using quantitative PCR (Primary outcome). Secondary outcomes included total fecal bifidobacteria and NEC≥Stage II. Categorical and continuous outcomes were analysed using Chi-square and Mann-Whitney tests, and McNemar and Wilcoxon signed-rank tests for paired comparisons.

Results: A total of 159 neonates (Probiotic: 79, Placebo: 80) were enrolled. Maternal and neonatal demographic characteristics were comparable between the groups. The proportion of neonates with detectable B. breve increased significantly post intervention: Placebo: [S1:2/66 (3%), S2: 25/66 (38%), p<0.001] Probiotic: [S1: 29/74 (40%), S2: 67/74 (91%), p<0.001]. Median S1 B. breve counts in both groups were below detection (<4.7 log cells x g(-1)), increasing significantly in S2 for the probiotic group (log 8.6) while remaining <4.7 log in the control group (p<0.001). There were no adverse effects including probiotic sepsis and no deaths. NEC≥Stage II occurred in only 1 neonate (placebo group).

Conclusion: B. breve M-16V is a suitable probiotic strain for routine use in preterm neonates.

Trial registration: Australia New Zealand Clinical Trial Registry ACTRN 12609000374268.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. CONSORT Flow Diagram.
See this image and copyright information in PMC

References

    1. Neu J, Walker WA (2011) Necrotizing enterocolitis. NEJ Med 364: 255–264. - PMC - PubMed
    1. Lin PW, Stoll BJ (2006) Necrotising enterocolitis. Lancet 368 9543: 1271–83. - PubMed
    1. Jain L (2013) Necrotizing enterocolitis prevention: art or science? Clin Perinatol 40 1: xiii–xv doi: 10.1016/j.clp.2013.01.002 - DOI - PubMed
    1. FAO/WHO Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. 2001. Available: http://www.who.int/foodsafety/publications/fs_management/en/probiotics.pdf. Accessed 2012 June 4.
    1. Bermudez-Brito M, Plaza-Díaz J, Muñoz-Quezada S, Gómez-Llorente C, Gil A (2012) Probiotic mechanisms of action. Ann Nutr Metab 61 2: 160–74. - PubMed

Publication types